Hydrodolasetron (CAS 127951-99-9)
QUICK LINKS
Hydrodolasetron is a metabolite of dolasetron, primarily explored in the context of pharmacodynamic studies. In research applications, it is used to understand the metabolic pathways of its parent compound, providing insights into how the body processes and eliminates such chemicals. Investigations involving hydrodolasetron often focus on its interaction with biological systems, analyzing its affinity for and effect on various receptors and transport mechanisms within the body. By monitoring the presence and concentration of hydrodolasetron in biological samples, researchers can trace the metabolic fate of dolasetron and evaluate factors that may influence its biotransformation. This compound also serves as a useful tool in the development of analytical methods, where it may act as a reference standard to ensure the accuracy and reliability of assay results in the study of metabolite profiles.
Hydrodolasetron (CAS 127951-99-9) References
- Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. | Wolf, H. 2000. Scand J Rheumatol Suppl. 113: 37-45. PMID: 11028830
- Optimization of sample pretreatment methods for simultaneous determination of dolasetron and hydrodolasetron in human plasma by HPLC-ESI-MS. | Hu, Y., et al. 2012. J Chromatogr Sci. 50: 785-91. PMID: 22645289
- Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery. | Balfour, JA. and Goa, KL. 1997. Drugs. 54: 273-98. PMID: 9257083
- Pharmacokinetics of dolasetron after oral and intravenous administration of dolasetron mesylate in healthy volunteers and patients with hepatic dysfunction. | Stubbs, K., et al. 1997. J Clin Pharmacol. 37: 926-36. PMID: 9505984
- Lack of Effect of Aprepitant on Hydrodolasetron Pharmacokinetics in CYP2D6 Extensive and Poor Metabolizers | and Dr Susie Xiujiang Li PhD, Mr Edward Pequignot MS, Ms Deborah Panebianco MS, Dr Paul Lupinacci PhD, Dr Anup Majumdar PhD, Dr Laura Rosen MD, PhD, Ms Tuli Ahmed MS, Dr Jane E. Royalty MD, Dr Thomas H. Rushmore PhD, Dr M. Gail Murphy MD, Dr Kevin J. Petty MD, PhD. July 2006. The Journal of Clinical Pharmacology. Volume46, Issue7: Pages 792-801.
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Hydrodolasetron, 5 mg | sc-490638 | 5 mg | $398.00 |